These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 20696321)

  • 1. Pathophysiological roles for purines: adenosine, caffeine and urate.
    Morelli M; Carta AR; Kachroo A; Schwarzschild MA
    Prog Brain Res; 2010; 183():183-208. PubMed ID: 20696321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do caffeine and more selective adenosine A
    Chen JF; Schwarzschild MA
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
    Kalda A; Yu L; Oztas E; Chen JF
    J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
    Chen JF
    Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutathione-Mediated Neuroprotective Effect of Purine Derivatives.
    Matsumura N; Aoyama K
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease.
    Gołembiowska K; Wardas J; Noworyta-Sokołowska K; Kamińska K; Górska A
    Neurotox Res; 2013 Jul; 24(1):29-40. PubMed ID: 23296550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.
    Xu K; Di Luca DG; Orrú M; Xu Y; Chen JF; Schwarzschild MA
    Neuroscience; 2016 May; 322():129-37. PubMed ID: 26905951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A2A receptors in neuroprotection of dopaminergic neurons.
    Pedata F; Pugliese AM; Melani A; Gianfriddo M
    Neurology; 2003 Dec; 61(11 Suppl 6):S49-50. PubMed ID: 14663010
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.
    Szabó N; Kincses ZT; Vécsei L
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):441-55. PubMed ID: 21332415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on adenosine A2A receptors as drug target in Parkinson's disease.
    Vallano A; Fernandez-Duenas V; Pedros C; Arnau JM; Ciruela F
    CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):659-69. PubMed ID: 21838670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caffeine as a psychomotor stimulant: mechanism of action.
    Fisone G; Borgkvist A; Usiello A
    Cell Mol Life Sci; 2004 Apr; 61(7-8):857-72. PubMed ID: 15095008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological interactions between adenosine A
    Pinna A; Serra M; Marongiu J; Morelli M
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S37-S44. PubMed ID: 33349579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
    Chen JF; Fredduzzi S; Bastia E; Yu L; Moratalla R; Ongini E; Schwarzschild MA
    Neurology; 2003 Dec; 61(11 Suppl 6):S74-81. PubMed ID: 14663016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
    Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
    PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the adenosine A
    Zhao Y; Zhou YG; Chen JF
    Chin J Traumatol; 2024 May; 27(3):125-133. PubMed ID: 37679245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine and a selective adenosine A2A receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice.
    Hsu CW; Wang CS; Chiu TH
    J Biomed Sci; 2010 Jan; 17(1):4. PubMed ID: 20074377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
    Singh S; Singh K; Gupta SP; Patel DK; Singh VK; Singh RK; Singh MP
    Brain Res; 2009 Aug; 1283():115-26. PubMed ID: 19520064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer.
    Ferré S; Bonaventura J; Tomasi D; Navarro G; Moreno E; Cortés A; Lluís C; Casadó V; Volkow ND
    Neuropharmacology; 2016 May; 104():154-60. PubMed ID: 26051403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
    Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
    Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease.
    Kachroo A; Schwarzschild MA
    Ann Neurol; 2012 Feb; 71(2):278-82. PubMed ID: 22367999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.